The experience of using acetylsalicylic acid in a comorbid patient with cad and type 2 diabetes

Abstract

The CVD death rates remain high now. The concurrent course of coronary artery disease (CAD) and diabetes mellitus (DM) has an unfavourable prognosis, requires specific therapy and the use of measures to prevent severe complications. DM sometimes hinders the timely diagnosis of CAD, which in this case is characterized by an atypical course and has no florid symptoms. This often causes serious pathological complications or death. The atherothrombosis forms the basis of pathogenesis of severe conditions. Atherothrombosis is not only a generalized, but also a constantly progressive disease, for which reason it is necessary to carry out both primary and secondary prevention. According to the existing guidelines of European Society of Cardiology and Society of Cardiology of Russian Federation, acetylsalicylic acid (ASA) is recommended at small doses as the first-line drug for the prevention of vascular events in patients with CAD. This article discusses the experience of using ASA according to the conducted studies and in practical medicine by the clinical example of a female patient.

Keywords

• coronary artery disease
• diabetes mellitus
• cardiovascular complications
• comorbidity
• primary prevention
• secondary prevention
• antiplatelet therapy
• acetylsalicylic acid